'Plasma first' approach for detecting epidermal growth factor receptor mutation in advanced non-small cell lung carcinoma.
EGFR
Liquid biopsy
NSCLC
Plasma first
Turnaround time
Journal
Journal of cancer research and clinical oncology
ISSN: 1432-1335
Titre abrégé: J Cancer Res Clin Oncol
Pays: Germany
ID NLM: 7902060
Informations de publication
Date de publication:
27 Jul 2024
27 Jul 2024
Historique:
received:
23
03
2024
accepted:
31
05
2024
medline:
28
7
2024
pubmed:
28
7
2024
entrez:
27
7
2024
Statut:
epublish
Résumé
The treatment approach for recently diagnosed advanced non-small cell lung cancer (NSCLC) with EGFR mutations primarily relies on confirming the tissue diagnosis as non-squamous NSCLC. This routine clinical practice of tissue diagnosis imposes several barriers and delays in turnaround time (TAT) for biomarker testing, significantly delaying the time to treatment. The objective of this study is to investigate the 'plasma first' approach for detection of EGFR mutation in advanced stage treatment naïve NSCLC patients. We prospectively collected blood samples of treatment naïve patients with clinical and radiological suspicion of advanced stage NSCLC prior to obtaining tissue biopsy. Plasma cfDNA was tested for EGFR mutation using two different methods. We compared the sensitivity and TAT of liquid biopsy with tissue biopsy. In total, we analyzed plasma cell-free DNA (cfDNA) of 236 patients suspected of having advanced NSCLC for EGFR mutations. We observed a notably shorter turnaround time (TAT) of 3 days, which was significantly quicker compared to the 12-day TAT for tissue biopsy (p < 0.05). The ddPCR method had a sensitivity of 82.8%, which was higher than 66.34% sensitivity of ARMS-PCR. The current study also highlights that there is no significant difference in the clinical outcome of the patients whether treated based on liquid biopsy only or tissue biopsy (median progression-free survival of 11.56 vs. 11.9 months; p = 0.94). Utilizing a 'plasma first' strategy, given its shorter turnaround time, strong positive concordance and comparable outcomes to tissue biopsy, emerges as a highly specific and reliable method for detecting EGFR mutations in advanced-stage NSCLC.
Identifiants
pubmed: 39066920
doi: 10.1007/s00432-024-05828-w
pii: 10.1007/s00432-024-05828-w
doi:
Substances chimiques
ErbB Receptors
EC 2.7.10.1
EGFR protein, human
EC 2.7.10.1
Biomarkers, Tumor
0
Cell-Free Nucleic Acids
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
371Subventions
Organisme : All India Institute of Medical Sciences intramural collaborative project
ID : AC-26
Organisme : All India Institute of Medical Sciences intramural collaborative project
ID : AC-26
Organisme : Department of Health Research-Indian Council of Medical Research project
ID : I-1180
Informations de copyright
© 2024. The Author(s).
Références
Aggarwal C et al (2019) Clinical implications of plasma-based genotyping with the delivery of personalized therapy in metastatic non-small cell Lung Cancer. JAMA Oncol 5(2):173–180. https://doi.org/10.1001/jamaoncol.2018.4305
doi: 10.1001/jamaoncol.2018.4305
pubmed: 30325992
Aldea M et al (2020) Circulating tumor DNA analysis for patients with Oncogene-Addicted NSCLC with isolated Central Nervous System Progression. J Thorac Oncology: Official Publication Int Association Study Lung Cancer vol 15(3):383–391. https://doi.org/10.1016/j.jtho.2019.11.024
doi: 10.1016/j.jtho.2019.11.024
Benbrahim Z, Antonia T, Mellas N (2018) EGFR mutation frequency in Middle East and African non-small cell lung cancer patients: a systematic review and meta-analysis. BMC Cancer 18(1):891. https://doi.org/10.1186/s12885-018-4774-y
doi: 10.1186/s12885-018-4774-y
pubmed: 30217176
pmcid: 6137870
Burnett H et al (2021) Epidemiological and clinical burden of EGFR exon 20 insertion in advanced non-small cell lung cancer: a systematic literature review. PloS One vol 16. 3 e02476208 Mar https://doi.org/10.1371/journal.pone.0247620
Canale M, Pasini L, Bronte G, Delmonte A, Cravero P, Crinò L, Ulivi P (2019) Role of liquid biopsy in oncogene-addicted non-small cell lung cancer. Translational lung cancer Res 8(Suppl 3):S265–S279. https://doi.org/10.21037/tlcr.2019.09.15
doi: 10.21037/tlcr.2019.09.15
Cescon DW, Bratman SV, Chan SM, Siu LL (2020) Circulating tumor DNA and liquid biopsy in oncology. Nat cancer 1(3):276–290. https://doi.org/10.1038/s43018-020-0043-5
doi: 10.1038/s43018-020-0043-5
pubmed: 35122035
Chan BA, Hughes BG (2015) Targeted therapy for non-small cell lung cancer: current standards and the promise of the future. Translational lung cancer Res 4(1):36–54. https://doi.org/10.3978/j.issn.2218-6751.2014.05.01
doi: 10.3978/j.issn.2218-6751.2014.05.01
Chouaid C et al (2021) A real-world study of patients with Advanced non-squamous non-small cell Lung Cancer with EGFR exon 20 insertion: clinical characteristics and outcomes. Target Oncol vol 16(6):801–811. https://doi.org/10.1007/s11523-021-00848-9
doi: 10.1007/s11523-021-00848-9
Chougule A, Prabhash K, Noronha V, Joshi A, Thavamani A, Chandrani P, Upadhyay P, Utture S, Desai S, Jambhekar N, Dutt A (2013) Frequency of EGFR mutations in 907 lung adenocarcioma patients of Indian ethnicity. PLoS ONE 8(10):e76164. https://doi.org/10.1371/journal.pone.0076164
doi: 10.1371/journal.pone.0076164
pubmed: 24124538
pmcid: 3790706
Chuang JC, Neal JW (2015) Crizotinib as first line therapy for advanced ALK-positive non-small cell lung cancers. Translational lung cancer Res 4(5):639–641. https://doi.org/10.3978/j.issn.2218-6751.2015.03.06
doi: 10.3978/j.issn.2218-6751.2015.03.06
Cui W et al (2022) Up-front cell-free DNA next generation sequencing improves target identification in UK first line advanced non-small cell lung cancer (NSCLC) patients. Eur J cancer (Oxford England: 1990 171:44–54. https://doi.org/10.1016/j.ejca.2022.05.012
doi: 10.1016/j.ejca.2022.05.012
Detection and quantification of EGFR T790M mutation in liquid biopsies by droplet digital PCR. Translational lung cancer research, 10(3), 1200–1208. https://doi.org/10.21037/tlcr-20-1010
Diaz LA Jr, Bardelli A (2014) Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncology: Official J Am Soc Clin Oncol 32(6):579–586. https://doi.org/10.1200/JCO.2012.45.2011
doi: 10.1200/JCO.2012.45.2011
Douillard J-Y et al Gefitinib treatment in EGFR mutated caucasian NSCLC: circulating-free tumor DNA as a surrogate for determination of EGFR status. J Thorac Oncol 9,9 (2014): 1345–1353. https://doi.org/10.1097/JTO.0000000000000263
Ettinger DS et al (2022) Non-small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice guidelines in Oncology. J Natl Compr Cancer Network: JNCCN 20(5):497–530. https://doi.org/10.6004/jnccn.2022.0025
doi: 10.6004/jnccn.2022.0025
pubmed: 35545176
Filipits M et al (2023) Epidermal growth factor receptor T790M mutation testing in Non-small Cell Lung Cancer: An International Collaborative Study to Assess Molecular EGFR T790M testing in Liquid Biopsy. Cancers 15(13):3528. https://doi.org/10.3390/cancers15133528
doi: 10.3390/cancers15133528
pubmed: 37444638
pmcid: 10340641
García-Pardo M et al (2023) Association of circulating Tumor DNA Testing before tissue diagnosis with time to treatment among patients with suspected Advanced Lung Cancer: the ACCELERATE Nonrandomized Clinical Trial. JAMA Netw open 6(7):e2325332. https://doi.org/10.1001/jamanetworkopen.2023.25332
doi: 10.1001/jamanetworkopen.2023.25332
pubmed: 37490292
pmcid: 10369925
Hofman P et al (2023) Real-world EGFR testing practices for non-small-cell lung cancer by thoracic pathology laboratories across Europe. ESMO open 8(5):101628. https://doi.org/10.1016/j.esmoop.2023.101628
doi: 10.1016/j.esmoop.2023.101628
pubmed: 37713929
pmcid: 10594022
Hsiue EH-C et al (2016) Profile of the therascreen® EGFR RGQ PCR kit as a companion diagnostic for gefitinib in non-small cell lung cancer. Expert Rev Mol Diagnostics vol 16(12):1251–1257. https://doi.org/10.1080/14737159.2016.1248414
doi: 10.1080/14737159.2016.1248414
Huang YH, Tseng JS, Hsu KH, Chen KC, Su KY, Yu SL, Chen JJW, Yang TY, Chang GC (2021) Publisher correction: the impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M. Sci Rep 11(1):17646. https://doi.org/10.1038/s41598-021-97248-w
doi: 10.1038/s41598-021-97248-w
pubmed: 34462521
pmcid: 8405629
Hung MS, Wu YF, Chen YC (2019) Efficacy of chemoradiotherapy versus radiation alone in patients with inoperable locally advanced non-small-cell lung cancer: a meta-analysis and systematic review. Medicine 98(27):e16167. https://doi.org/10.1097/MD.0000000000016167
doi: 10.1097/MD.0000000000016167
pubmed: 31277121
pmcid: 6635168
Jones GS, Baldwin DR (2018) Recent advances in the management of lung cancer. Clin Med 18(Suppl 2):s41–s46. https://doi.org/10.7861/clinmedicine.18-2-s41
doi: 10.7861/clinmedicine.18-2-s41
Kawahara A et al (2015) Epidermal growth factor receptor mutation status in cell-free DNA supernatant of bronchial washings and brushings. Cancer Cytopathol 123(10):620–628. https://doi.org/10.1002/cncy.21583
doi: 10.1002/cncy.21583
pubmed: 26235264
Lee Y et al (2020) Turnaround Time of Plasma Next-Generation Sequencing in Thoracic Oncology Patients: A Quality Improvement Analysis. JCO precision oncology, 4, PO.20.00121. https://doi.org/10.1200/PO.20.00121
Leighl, Natasha B et al (2019) Clinical utility of Comprehensive Cell-free DNA analysis to identify genomic biomarkers in patients with newly diagnosed metastatic non-small cell Lung Cancer. Clin cancer Research: Official J Am Association Cancer Res 25(15):4691–4700. https://doi.org/10.1158/1078-0432.CCR-19-0624
doi: 10.1158/1078-0432.CCR-19-0624
Li Y, Xu Y, Wu X, He C, Liu Q, Wang F (2019) Comprehensive analysis of EGFR T790M detection by ddPCR and ARMS-PCR and the effect of mutant abundance on the efficacy of osimertinib in NSCLC patients. J Thorac Disease 11(7):3004–3014. https://doi.org/10.21037/jtd.2019.07.42
doi: 10.21037/jtd.2019.07.42
Lindeman NI et al (2018) Updated Molecular Testing Guideline for the selection of Lung Cancer patients for treatment with targeted tyrosine kinase inhibitors: Guideline from the College of American Pathologists, the International Association for the study of Lung Cancer, and the Association for Molecular Pathology. Arch Pathol Lab Med 142(3):321–346. https://doi.org/10.5858/arpa.2017-0388-CP
doi: 10.5858/arpa.2017-0388-CP
pubmed: 29355391
Liu S et al (2022) Apr. TP53 Co-Mutations in Advanced EGFR-Mutated Non-Small Cell Lung Cancer: Prognosis and Therapeutic Strategy for Cancer Therapy. Frontiers in oncology vol. 12 860563. 4 https://doi.org/10.3389/fonc.2022.860563
Lu CF, Liao CY, Chao HS, Chiu HY, Wang TW, Lee Y, Chen JR, Shiao TH, Chen YM, Wu YT (2023) A radiomics-based deep learning approach to predict progression free-survival after tyrosine kinase inhibitor therapy in non-small cell lung cancer. Cancer Imaging: Official Publication Int Cancer Imaging Soc 23(1):9. https://doi.org/10.1186/s40644-023-00522-5
doi: 10.1186/s40644-023-00522-5
Maemondo M et al (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362(25):2380–2388. https://doi.org/10.1056/NEJMoa0909530
doi: 10.1056/NEJMoa0909530
pubmed: 20573926
Markus H et al (2018) Evaluation of pre-analytical factors affecting plasma DNA analysis. Sci Rep 8(1):7375. https://doi.org/10.1038/s41598-018-25810-0
doi: 10.1038/s41598-018-25810-0
pubmed: 29743667
pmcid: 5943304
Melosky B, Kambartel K, Häntschel M, Bennetts M, Nickens DJ, Brinkmann J, Kayser A, Moran M, Cappuzzo F (2022) Worldwide Prevalence of epidermal growth factor receptor mutations in Non-small Cell Lung Cancer: a Meta-analysis. Mol Diagn Ther 26(1):7–18. https://doi.org/10.1007/s40291-021-00563-1
doi: 10.1007/s40291-021-00563-1
pubmed: 34813053
Mosele F et al (2020) Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. Annals Oncology: Official J Eur Soc Med Oncol 31(11):1491–1505. https://doi.org/10.1016/j.annonc.2020.07.014
doi: 10.1016/j.annonc.2020.07.014
Passaro A et al (2022) ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer. Annals of oncology: official journal of the European Society for Medical Oncology. 33(5):466–487. https://doi.org/10.1016/j.annonc.2022.02.003
Paweletz, Cloud P et al (2016) Bias-Corrected targeted Next-Generation sequencing for Rapid, Multiplexed detection of actionable alterations in cell-free DNA from Advanced Lung Cancer patients. Clin cancer Research: Official J Am Association Cancer Res 22(4):915–922. https://doi.org/10.1158/1078-0432.CCR-15-1627-T
doi: 10.1158/1078-0432.CCR-15-1627-T
Pisapia P, Malapelle U, Troncone G (2019) Liquid Biopsy and Lung Cancer. Acta Cytol 63(6):489–496. https://doi.org/10.1159/000492710
doi: 10.1159/000492710
pubmed: 30566947
Planchard D et al (2018) Metastatic non-small cell lung cancer: ESMO Clinical Practice guidelines for diagnosis, treatment and follow-up. Annals Oncology: Official J Eur Soc Med Oncol 29(Suppl 4):iv192–iv237. https://doi.org/10.1093/annonc/mdy275
doi: 10.1093/annonc/mdy275
Qian H, Zhang Y, Xu J, He J, Gao W (2021) Progress and application of circulating tumor cells in non-small cell lung cancer. Mol Therapy Oncolytics 22:72–84. https://doi.org/10.1016/j.omto.2021.05.005
doi: 10.1016/j.omto.2021.05.005
Raez LE, Brice K, Dumais K, Lopez-Cohen A, Wietecha D, Izquierdo PA, Santos ES, Powery HW (2023) Liquid Biopsy Versus tissue biopsy to Determine Front Line Therapy in Metastatic Non-small Cell Lung Cancer (NSCLC). Clin Lung Cancer 24(2):120–129. https://doi.org/10.1016/j.cllc.2022.11.007
doi: 10.1016/j.cllc.2022.11.007
pubmed: 36585341
Rolfo C, Russo A (2023) Exploiting the full potential of Novel agents Targeting EGFR exon 20 insertions in Advanced NSCLC: next-generation sequencing outperforms polymerase chain reaction-based testing. J Thorac Oncol : Official Publication the 18(6):674–677. International Association for the Study of Lung Cancer vol10.1016/j.jtho.2023.02.020
doi: 10.1016/j.jtho.2023.02.020
Rolfo C et al (2021) Liquid Biopsy for Advanced NSCLC: a Consensus Statement from the International Association for the study of Lung Cancer. J Thorac Oncology: Official Publication Int Association Study Lung Cancer 16(10):1647–1662. https://doi.org/10.1016/j.jtho.2021.06.017
doi: 10.1016/j.jtho.2021.06.017
Rossi S et al (2019) Impact of exon 19 deletion subtypes in EGFR-Mutant metastatic non-small-cell lung Cancer treated with first-line tyrosine kinase inhibitors. Clin lung cancer vol 20(2):82–87. https://doi.org/10.1016/j.cllc.2018.10.009
doi: 10.1016/j.cllc.2018.10.009
Russo A et al (2024) Liquid Biopsy of Lung Cancer before pathological diagnosis is Associated with shorter time to treatment. JCO Precision Oncol 8:e2300535. https://doi.org/10.1200/PO.23.00535
doi: 10.1200/PO.23.00535
Sahoo R, Harini VV, Babu VC, Okaly P, Rao GV, Nargund S, Venkataswamy A, Rao E, R., Kumar BS (2011) Screening for EGFR mutations in lung cancer, a report from India. Lung cancer (Amsterdam Netherlands) 73(3):316–319. https://doi.org/10.1016/j.lungcan.2011.01.004
doi: 10.1016/j.lungcan.2011.01.004
pubmed: 21315473
Satapathy S et al (2021) EGFR mutation testing on plasma and urine samples: A pilot study evaluating the value of liquid biopsy in lung cancer diagnosis and management. Current problems in cancer vol. 45,6 : 100722. https://doi.org/10.1016/j.currproblcancer.2021.10072227 . Silveira, Catarina (2021)
Shen C-I et al (2022) Aug. Real-world evidence of the intrinsic limitations of PCR-based EGFR mutation assay in non-small cell lung cancer. Scientific reports vol. 12,1 13566. 9 https://doi.org/10.1038/s41598-022-17394-7
Singh V, Nambirajan A, Malik PS, Thulkar S, Pandey RM, Luthra K, Arava S, Ray R, Mohan A, Jain D (2020) Spectrum of uncommon and compound epidermal growth factor receptor mutations in non-small-cell lung carcinomas with treatment response and outcome analysis: a study from India. Lung Cancer 149:53–60. https://doi.org/10.1016/j.lungcan.2020.07.038
doi: 10.1016/j.lungcan.2020.07.038
pubmed: 32971387
Singh N et al (2022) Therapy for Stage IV Non-small-cell Lung Cancer with driver alterations: ASCO Living Guideline. J Clin Oncology: Official J Am Soc Clin Oncol 40(28):3310–3322. https://doi.org/10.1200/JCO.22.00824
doi: 10.1200/JCO.22.00824
Smolle E, Taucher V, Lindenmann J, Pichler M, Smolle-Juettner FM (2021) Liquid biopsy in non-small cell lung cancer-current status and future outlook-a narrative review. Translational lung cancer Res 10(5):2237–2251. https://doi.org/10.21037/tlcr-21-3
doi: 10.21037/tlcr-21-3
Song P, Wu LR, Yan YH, Zhang JX, Chu T, Kwong LN, Patel AA, Zhang DY (2022) Limitations and opportunities of technologies for the analysis of cell-free DNA in cancer diagnostics. Nat Biomedical Eng 6(3):232–245. https://doi.org/10.1038/s41551-021-00837-3
doi: 10.1038/s41551-021-00837-3
Soria-Comes T, Palomar-Abril V, Ureste MM, Guerola MT, Maiques ICM (2020) Real-World Data of the correlation between EGFR determination by Liquid Biopsy in non-squamous non-small cell Lung Cancer (NSCLC) and the EGFR Profile in Tumor Biopsy. Pathol Oncol Research: POR 26(2):845–851. https://doi.org/10.1007/s12253-019-00628-x
doi: 10.1007/s12253-019-00628-x
Suryavanshi M et al (2018) The detection of primary and secondary EGFR mutations using droplet digital PCR in patients with nonsmall cell lung cancer. Lung India: Official Organ Indian Chest Soc vol 35(5):384–389. https://doi.org/10.4103/lungindia.lungindia_472_17
doi: 10.4103/lungindia.lungindia_472_17
Thakur S et al (2024) Mar. Pleural effusion supernatant: a reliable resource for cell-free DNA in molecular testing of lung cancer. Journal of the American Society of Cytopathology, S2213-2945(24)00026 – 7. 29 https://doi.org/10.1016/j.jasc.2024.03.006
Trigg RM, Martinson LJ, Parpart-Li S, Shaw JA (2018) Factors that influence quality and yield of circulating-free DNA: a systematic review of the methodology literature. Heliyon 4(7):e00699. https://doi.org/10.1016/j.heliyon.2018.e00699
doi: 10.1016/j.heliyon.2018.e00699
pubmed: 30094369
pmcid: 6074610
Vokes NI et al (2022) Concurrent TP53 mutations facilitate Resistance Evolution in EGFR-Mutant Lung Adenocarcinoma. Journal of thoracic oncology: official publication of the International Association for the study of Lung Cancer. 17(6):779–792. https://doi.org/10.1016/j.jtho.2022.02.011
Wei B, Zhao C, Li J, Zhao J, Ren P, Yang K, Yan C, Sun R, Ma J, Guo Y (2019) Combined plasma and tissue genotyping of EGFR T790M benefits NSCLC patients: a real-world clinical example. Mol Oncol 13(5):1226–1234. https://doi.org/10.1002/1878-0261.12481
doi: 10.1002/1878-0261.12481
pubmed: 30927306
pmcid: 6487696
Wu W et al (2020) Jan. Comparison of the SuperARMS and ARMS for detecting EGFR mutations in liquid-based cytology specimens from NSCLC patients. Diagnostic pathology vol. 15,1 9. 31 https://doi.org/10.1186/s13000-019-0910-5
Zhao C et al (2020) The impact of EGFR exon 19 deletion subtypes on clinical outcomes in non-small cell lung cancer. Translational lung cancer Res vol 9(4):1149–1158. https://doi.org/10.21037/tlcr-19-359
doi: 10.21037/tlcr-19-359
Zhu G et al Highly sensitive Droplet Digital PCR method for detection of EGFR-Activating mutations in plasma cell-free DNA from patients with Advanced Non-small Cell Lung Cancer. J Mol Diagnostics: JMD vol. 17,3 (2015): 265–272. https://doi.org/10.1016/j.jmoldx.2015.01.004